Abstract
BackgroundBlockade of PD-1 or PD-L1 (PD-1 blockade) with antibodies has revolutionized treatment options for patients with non-small cell lung cancer particularly with tumors that don’t present any targetable mutations. However,...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have